T 0294/20 (NLPHL/DANA-FARBER) of 26.10.2023

European Case Law Identifier: ECLI:EP:BA:2023:T029420.20231026
Date of decision: 26 October 2023
Case number: T 0294/20
Petition for review of: -
Application number: 11162681.8
IPC class: A61K 39/00 A61K 38/17 C07K 16/28 G01N 33/574 A61K 31/713 G01N 33/50
Language of proceedings: English
Distribution: No distribution (D)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: -
Abstracts for this decision: Abstract on Article 083 EPC
Application title: Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death1 (PD-1) pathway
Applicant name: Dana-Farber Cancer Institute, Inc.
The Brigham and Women's Hospital, Inc.
Emory University
The President and Fellows of Harvard College
Opponent name: Ares Trading S.A.
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Janssen Biotech, Inc.
Sanofi
Board: 3.3.04
Headnote: -
Relevant legal provisions: European Patent Convention Art 83
Keywords: Sufficiency of disclosure - (no)
Catchword: -
Cited cases: G 0001/03 G 0002/21 T 0609/02 T 1329/04 T 0895/13 T 0950/13
Citing cases: -

Order

For these reasons it is decided that:

The appeal is dismissed.